The RefleXion platform is the only dual-treatment modality platform with near diagnostic quality kVCT imaging that delivers both breakthrough SCINTIX® autonomous radiotherapy and IMRT, SBRT and SRS. With reimbursement and product support services designed for freestanding cancer centers, the RefleXion platform can serve as the backbone to your practice.
SCINTIX Therapy is now reimbursed in freestanding centers with payment rates established by Medicare Administrative Contractors (MACs). This breakthrough technology is now an option for the ~ 40% of Americans receiving radiation therapy in this site of service. Professional payment rates have also been established by several MACs for radiation oncologists practicing in both hospital outpatient departments and freestanding centers.
The RefleXion platform with SCINTIX therapy treats multiple tumors in a single treatment planto streamline the workflow andenable efficient treatment of incremental patients with metastatic disease. A hybrid, multi-target treatment (MTT)2 plan can include SBRT tumors anda SCINTIX therapy tumor.
SCINTIX technology automates targeting and motion management for both expected and unexpected shifts, such as patient movement, so when the tumor moves, the dose automatically moves too.And early clinical cases have demonstratedup to 50% reduction3 in the volume treated with SCINTIX therapy, sparing more healthy tissue.
The RefleXion platformdelivers conventional radiotherapy (IMRT, SBRT, SRS) guided by state-of-the-artkVCT imaging and is cleared for all solid tumors, while SCINTIX therapy is cleared to treat lung and bone tumors arising from primary or metastatic disease. This versatile platform is designed to fit in your existing LINAC vault with minimum shielding requirements to streamline implementation costs.
1 https://docs.house.gov/meetings/IF/IF14/20171108/106599/HHRG-115-IF14-Wstate-KavanaghB-20171108.pdf 2 Multi-target treatments (MTT) are integrated into the FDA-cleared SCINTIX therapy indications for use workflow. MTT enhances dose optimization
review for delivery to more than one target. 3Individual results may vary.
